Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company focusing on developing and commercializing medicines to treat central nervous system (CNS), disorders. The company's principal product candidate, brexanolone for intravenous (IV), a naturally occurring neuroactive steroid is being developed as a treatment for post-partum depression (PPD). The company's other product candidates, SAGE-217 a neuroactive steroid is being developed as a potential treatment for major-depressive disorder, bipolar depression, PPD, Parkinson's disease and sleep disorders. The company's SAGE-324 and SAGE-689 candidates are at earlier stages of development with a focus on both acute and chronic CNS disorders.
  • TickerSAGE
  • ISINUS78667J1088
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

Laura Chico

SAGE_20190521

Wedbush Research

Wedbush Morning Call - Jul 16 2019 6:50AM

Laura Chico

Ahead of 2Q19 Biotech Reporting - Thoughts on Commercial Names

Laura Chico

In A FutureCast Age: Thoughts Ahead of SAGE's R&D Event

ValuEngine Rating and Forecast Report for SAGE

ValuEngine Rating and Forecast Report for SAGE

Laura Chico

SAGE_20190521

Wedbush Research

Wedbush Morning Call - Jul 16 2019 6:50AM

Laura Chico

Ahead of 2Q19 Biotech Reporting - Thoughts on Commercial Names

Laura Chico

In A FutureCast Age: Thoughts Ahead of SAGE's R&D Event

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

1 director sold after exercising options/sold

A director at Sage Therapeutics Inc sold after exercising options/sold 85,736 shares at 174.738USD and the significance rating of the trade was 93/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted und...

ValuEngine Rating and Forecast Report for SAGE

ValuEngine Rating and Forecast Report for SAGE

ValuEngine Rating and Forecast Report for SAGE

ValuEngine Rating and Forecast Report for SAGE

ValuEngine Rating and Forecast Report for SAGE

ValuEngine Rating and Forecast Report for SAGE

ValuEngine Rating and Forecast Report for SAGE

ValuEngine Rating and Forecast Report for SAGE

ValuEngine Rating and Forecast Report for SAGE

ValuEngine Rating and Forecast Report for SAGE

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

The S&P 500 is beginning to come off of short-term overbought extremes, consolidating near the confluence of key overhead resistance and the 200-day moving average. This level is roughly 2,817 on the S&P 500 and roughly 1,000 on the S&P 600 Small Cap index. Some consolidation or a mild pullback is possible in the near-term, which we believe would help alleviate current overbought readings and allow for a more orderly and meaningful move higher. This constructive outlook is supported by the themes highlighted below: • Internals are healthy. The S&P 500 advance/decline line is advancing to new ...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch